Following news of RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines, ...

Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that ...

Norovirus vaccines face significant hurdles, with virtually no success from past efforts from HilleVax and Vaxxart. But ...

Shares of Moderna Inc. MRNA slipped 2.31% to $41.83 Friday, on what proved to be an all-around mixed trading session for the ...

Analysts issued an Underperform rating for shares while reluanching coverage of large-cap U.S. pharma and biotech names.

Moderna's (NASDAQ:MRNA) mRNA-1647, its vaccine asset for cytomegalovirus (CMV), may not yield positive interim phase 3 data ...

In the chaotic early days of the pandemic, Wall Street scrambled to place bets on the companies that looked the most likely to thrive the uncharted waters that were rising all around us. The early ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 10.82% ...

Shares of Moderna Inc. MRNA sank 0.09% to $42.82 Thursday, on what proved to be an all-around dismal trading session for the ...

After several severe RSV cases were reported in a pediatric trial of Moderna's vaccine, the FDA has partially paused testing ...

2024 has been a generally outstanding year for the stock market, with the S&P 500 ( ^GSPC 0.82%) up by nearly 30% year to ...

Palantir, MicroStrategy, and Axon Enterprise are set to join the Nasdaq 100 Index on Monday, Dec. 23, replacing Super Micro ...